BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it concentrates its resources on an anticipated launch of its pivotal heart drug.
The subsidiary, a company called TheRAS that is developing treatments for cancers with mutations in the KRAS gene, will become BridgeBio Oncology Therapeutics. The spinout is backed by $200 million in private financing led by Cormorant Asset Management and Omega Funds, with participation from other firms including Deerfield Management and Google Ventures, BridgeBio said Thursday.
BridgeBio will still have an ownership stake in the new company, but it wouldn’t disclose how large. The spinout is advancing three drug candidates, one that’s being tested in a Phase 1 trial and two others that are preclinical.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.